Major Depressive Disorder Clinical Trials in O'Fallon, Missouri

4 studies are recruiting for major depressive disorder in O'Fallon, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

    X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

    Stage
    Phase 3
    Ages
    18 to 74
    Site
    Psychiatric Care and Research Center, O'Fallon, Missouri
    Locations
    50 in total
    Run by
    Xenon Pharmaceuticals Inc.

    See if you can join NCT07076407 on ClinicalTrials.gov

  2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Psychiatric Care and Research Center (PCRC), O'Fallon, Missouri
    Locations
    69 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT05850689 on ClinicalTrials.gov

  3. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, O'Fallon, Missouri
    Locations
    106 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06966401 on ClinicalTrials.gov

  4. A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, O'Fallon, Missouri
    Locations
    60 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07196501 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.